araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Hereditary Risk Factors for Thyroid Cancer

Summary: Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules.
  -  In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies.
  -  Individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.

Detailed description: The purpose of this research study is to learn more about risk factors for inherited thyroid cancer.
  The investigators would like to use the participant DNA to look for alterations in genes. The investigator will perform DNA sequencing and other genetic studies to identify errors in the genes that may contribute to the formation of thyroid nodules and cancer.

Eligibility: Inclusion Criteria:
  -  Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s).
  -  Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below).
  -  Individuals from families with a high suspicion of hereditary thyroid cancer:
  -  Families with a current or previous diagnosis of a thyroid cancer/nodule occurring in childhood (<18 years old).
  -  Families with a high suspicion of hereditary thyroid cancer/nodules other than above to include:
  -  Families with thyroid cancer in multiple individuals
  -  Families with thyroid cancer and a known genetic syndrome
  -  Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)
  Exclusion Criteria:
  -  Individuals who are unable to give informed consent.
  -  Individuals who are unable to complete study materials.

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: A Gene Hunting Study for Familial Papillary Thyroid Cancer

Summary: The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive.

Detailed description: The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). This can be accomplished in several ways, including loss of heterozygosity studies as well as comparative gene expression analysis. When possible, linkage analysis on families with multiple individuals affected with PTC may also help identify the putative gene(s).
  Study participants will be asked to:
  1. Complete family history and medical history questionnaires
  2. Sign a medical record release so that thyroid cancer pathology reports can be obtained
  3. Supply a blood sample for genetic studies
  4. Provide study related information to family members who are needed for family studies

Eligibility: Eligibility Criteria:
  -  Patients with a diagnosis of PTC and a family history of PTC
  -  Affected and unaffected family members of the proband*
  -  For familial cases (families with 2 or more cases of PTC), participation will be offered to all living family members with PTC or benign thyroid disease as well as selected unaffected first and second degree relatives. Participation may also be offered to spouses when needed for analyzing parent/offspring samples.

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: ctDNA in Patients With Thyroid Nodules

Summary: When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream. This circulating tumor DNA (ctDNA) can be detected by very sensitive, specialized laboratory tests. Measurement of ctDNA has been shown to be useful for following patients with known cancer. The purpose of this study is to examine blood specimens for the presence of ctDNA in individuals without known cancer who are scheduled to undergo a fine needle aspiration biopsy of the thyroid gland because of one or more thyroid nodules in order to see if the ctDNA test can detect a cancer at a very early stage. The results of this study should help define the role of ctDNA in the detection of early stage thyroid cancer and to define how sensitive it is (i.e. how well it picks up cancer when it is present) and how specific it is (i.e. how often is ctDNA found in patients with benign thyroid nodules).

Detailed description: After the participants with thyroid nodules or other abnormalities have undergone the informed consent process, they will have 30 milliliters (approximately two tablespoons) of blood drawn. This will be done prior to the performance of the fine needle aspiration biopsy of the thyroid. If the patient has indicated a desire to receive the results of their test, they will receive a written description, as will their physician. The patients will be contacted yearly for up to 5 years by the study staff to learn whether they have been found to have a diagnosis of thyroid or other cancer.

Eligibility: Inclusion Criteria:
  -  18 years of age or older;
  -  presence of one or more thyroid nodules who are going to have a fine needle aspiration biopsy performed as part of their normal care.
  Exclusion Criteria:
  -  Prior history of cancer excluding basal cell carcinoma of the skin.

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Proteomics of Papillary Thyroid Carcinoma

Summary: Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.

Detailed description: 1. Object: Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer.
  2. Clinical information, examination data: Information is obtained from medical record abstraction.
  3. Samples: Fresh frozen thyroid tissues from each sample group(normal histology, benign disease, papillary thyroid carcinoma with cervical lymph node metastasis, papillary thyroid carcinoma without cervical lymph node metastasis ).

Eligibility: Inclusion Criteria:
  -  Newly diagnosed papillary thyroid carcinoma.
  -  Undergo thyroidectomy according to the China thyroid association guidelines forthe Management of thyroid nodule and thyroid cancer.
  Exclusion Criteria:
  -  Current substance abuse/dependence.
  -  Daily tobacco and alcohol use.
  -  Whole neck irradiation or surgery.
  -  Prior cancer diagnosis or chemotherapy treatment.
  -  Active autoimmune disorder.
  -  Uncontrolled allergic condition or asthma.
  -  Chronic use of oral steroid medication.
  -  Hormone therapy (estrogen, progestin compounds).

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer

Summary: The objective of this study is to optimize the search by next-generation sequencing (NGS) mutations in the KRAS, BRAF and NRAS on circulating tumor DNA and compare the genetic profiles obtained with those from tumors embedded in paraffin


Eligibility: Inclusion Criteria:
  -  Patients with metastatic or locally advanced colorectal carcinoma with a KRAS, BRAF or NRAS mutation
  -  Age ≥ 18 years
  -  Patient information and written informed consent form signed
  -  Patient must be affiliated to a social security system
  Exclusion Criteria:
  -  Patients whose health-cons indicates a blood sample 10mL
  -  Age < 18 years
  -  Pregnant or breast feeding females
  -  Persons deprived of liberty or under supervision

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Summary: The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.


Eligibility: Inclusion Criteria:
  -  Advanced or metastatic cancer.
  -  Able to swallow tablets.
  -  For Part B, you will need to have colon cancer or non-small cell lung (NSCLC) cancer with KRAS and/or BRAF mutations.
  -  Discontinued all previous treatments for cancer and recovered from the acute effects from the therapy.
  Exclusion Criteria:
  -  Active infection (fungal, viral, or bacterial).
  -  Active cancer in your brain or spinal cord.
  -  Acute or chronic leukemia.
  -  Serious heart condition.
  -  Disease that requires immunosuppressant therapy.
  -  Diagnosis of inflammatory bowel disease.
  -  Major small bowel resection that interferes with your body's ability to absorb the oral medicine.
  -  Participated in other clinical trials investigating prexasertib or ralimetinib.
  -  Pregnant or breastfeeding.
  -  Other pre-existing conditions or medical history which your doctor will explain to you.

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Institut Paoli Calmettes Thyroid Cancer Database

Summary: Database of Institut Paoli-Calmettes patients diagnosed with thyroid cancer


Eligibility: Inclusion Criteria:
  -  Diagnosis of thyroid cancer
  Exclusion Criteria:
  -  Non applicable

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Genotyping 2 SNPs in Chinese Breast Cancers

Summary: The purpose of this study is to determine the frequency of two Single Nucleotide Polymorphisms (SNPs) by sanger-sequencing in Breast Cancers and healthy controls .

Detailed description: Since the 1990s breast cancers incidence of china has increased more than twice as fast as global rates. Chinese patients are responsible for 12.2% of all newly diagnosed breast cancers and 9.6% of all deaths to world breast cancers. Breast cancer is now the second frequently diagnosed cancer and is the leading cause of cancer-related death in Chinese women.
  Two of the most prevalent breast cancer susceptibility genes are BRCA1and BRCA2. However，because of population based Genetic heterogeneity, the frequency of BRCA1/BRCA2 mutation is not as high in Caucasian population as in China. Anyway, the mean age at diagnosis of breast cancer in China is almost 10 years younger and more cases are diagnosed before 40 than those in Caucasians. Therefore, it is believed that there are certain specific susceptibility loci in Chinese breast cancers.
  In preliminary experiments, investigators found two germline mutations may associate with Chinese breast cancers.
  The purpose of the study is to determine the frequency of two germline mutations by sanger-sequencing in a larger sample of Chinese breast cancers

Eligibility: Inclusion Criteria:
  -  Woman aged superior to 18 years old Inform consent signed Woman without breast cancer and family history of cancer
  Exclusion Criteria:
  -  No inform consent signed Patient under guardianship, curatorship Psychosocial disorder

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Active Surveillance of Papillary Thyroid Microcarcinoma

Summary: Papillary thyroid microcarcinoma are small thyroid cancer measuring 1cm or less. Most of this tumor are not palpable and are identified either through pathologic examination or from imaging modalities, such as CT scan or thyroid sono. Active surveillance of papillary microcarcinoma is to observe thyroid papillary cancer without immediate surgical approach. The purpose of this study is to understand more about the characteristics of papillary microcarcinoma, which has been known for "the cancer slowly progression"


Eligibility: Inclusion Criteria:
  1. < 1 cm solitary nodule
  2. Surrounded by ≥ 2 mm normal thyroid parenchyma
  3. Subcapsular locations not adjacent to surrounding structures, recurrent laryngeal nerve, trachea, or carotid artery
  4. No evidence of invasion to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery
  5. No extrathyroidal extension
  6. Clinically N0 and Clinically M0
  7. ≥ 18 years
  8. Combined severe comorbidities or Inoperable condition (optional)
  9. No wish to surgery and Willingness to accept active surveillance
  10. No history of radiotherapy on head and neck area
  11. Accepted by the Board of Thyroid Cancer Meeting
  Exclusion Criteria:
  1. ≥ 1 cm nodule and multifocal nodules regardless of size
  2. Papillary thyroid carcinoma variants associated with poor prognosis (tall cell variant, columnar variant, hobnail variant) or other types of thyroid cancer)
  3. Subcapsular locations adjacent to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery
  4. Evidence of invasion to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery
  5. Extrathyroidal extension
  6. Any of N1 or M1
  7. Documented increase in size according to America Thyroid Association (ATA) guideline in a previously confirmed Papillary thyroid microcarcinoma
  8. < 18 years
  9. Not willing to accept observational active surveillance approach

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.

Summary: To investigate the genetic mutations of patients with thyroid carcinoma and find molecular targets for therapy.

Detailed description: In previous studies, we have found highly prevalent TERT promoter mutations in aggressive thyroid cancers. So we plan to perform further research to investigate the genetic mutations of patients with thyroid carcinoma and find molecular targets for therapy.

Eligibility: Inclusion Criteria:
  -  Patient with thyroid nodule
  Exclusion Criteria:
  -  Coagulant function abnormality
  -  pregnant

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: The Establish of Specific Reference Ranges for Thyroid Tests in Pregnant Women

Summary: A descriptive analysis involving 300 healthy pregnant women to the establish of trimester-specific reference ranges for thyroid tests in pregnant women. 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range.

Detailed description: A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women. According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.

Eligibility: Inclusion Criteria:
  1. The people who lived in the city more than five years, aged between 19 and 45, or the single pregnancy women who registered or checked in Peking University international hospital would be enrolled.
  2. The pregnancy confirmed by the ultrasound or blood HCG test.
  3. In order to build a pregnancy reference range of normal pregnant women who must meet the NACB standard.
  Exclusion Criteria:
  1. The history of thyroid disorders.
  2. Goiter.
  3. Oral contraceptives or any drugs affected the function of thyroid.
  4. With other chronic autoimmune disease, malignant tumor, blood disease, etc
  5. Twin pregnancies and multiple pregnancies

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Study of LXH254 and LTT462 in NSCLC

Summary: To characterize safety and tolerability of LXH254 and LTT462 combination and identify a recommended dose and regimen.


Eligibility: Inclusion Criteria:
  -  Patients must have advanced or metastatic NSCLC
  -  Presence of KRAS or BRAF mutation in tumor tissue
  -  All patients participating in this clinical trial must have progressed following standard therapy or, in the opinion of the Investigator, no effective standard therapy exists, is tolerated, appropriate or is considered equivalent to study treatment.
  -  ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
  Exclusion Criteria:
  -  Dose expansion - Group 1: Prior treatment with a RAFi (including any BRAFi and pan-RAFi), MEKi and/or ERKi. Group 2: Prior treatment with an ERKi and/or a pan-RAFi.
  -  History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
  -  Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
  -  Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.
  -  Patients with Gilbert's syndrome or other heritable diseases of bile processing.
  Other protocol-defined inclusion/exclusion criteria may apply

Relevance to patient case: not relevant
Patient case: 40-year-old female with thyroid cancer; genetic feature: BRAF

Clinical trial: Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm

Summary: The prevalence of thyroid nodule is worldwide high. About 40% of normal population has thyroid nodules and about 5% are malignancy. It is important to differentiate malignancy from benign nodules because the management is completely different. Nowadays, the gold standard is fine needle aspiration cytology (FNAC) examination. The overall sensitivity and specificity is fair (~90%), but still has its limitation that some results are indeterminate in about 15% of the nodules. These obstacles are especially troublesome for papillary and follicular thyroid cancer that leads to delayed diagnosis, incomplete resection, and repeated operation. Preoperative evaluation of the prognosis is extraordinary important for cancer management. However, current prognostic scoring systems is only applicable after surgery. Hence, we urgently need a better risk-stratification system for individual-tailored treatment, and genetic-based computerized morphometry study seems to be the most realistic and promising one. The goal of this study is to propose a reliable method for diagnosis and prognosis of papillary thyroid cancer and follicular thyroid cancer through analyzing cellular morphologic characteristics.


Eligibility: Inclusion Criteria:
  -  patients who previously had received thyroid fine needle aspiration cytology examination
  Exclusion Criteria:
  -  patients who are younger than 20 years old

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer

Summary: Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy may kill more tumor cells.

Detailed description: OBJECTIVES:
  I. Determine the maximum tolerated dose of topotecan and chest irradiation in patients with non-small cell lung cancer.
  II. Determine the qualitative and quantitative toxic effects of this regimen in these patients.
  III. Determine the degree of antitumor activity of this regimen in these patients.
  OUTLINE: This is a dose escalation study of topotecan and thoracic radiotherapy.
  Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically proven non-small cell lung cancer
  -  Eligible for chest irradiation with 3,000 to 6,000 cGy (based upon standard radiotherapy indications)
  -  Measurable or evaluable disease
  -  Measurable disease defined as bidimensionally measurable lesion on physical exam or radiograph (CT or MRI acceptable)
  PATIENT CHARACTERISTICS:
  -  Age: 18 and over
  -  Performance status: 0-2
  -  Life expectancy: At least 12 weeks
  -  WBC at least 4,000/mm3
  -  Platelet count at least 100,000/mm3
  -  Bilirubin no greater than 1.5 mg/dL
  -  AST less than 3 times normal
  -  Alkaline phosphatase less than 3 times normal
  -  Creatinine no greater than 1.5 mg/dL
  -  Not pregnant or nursing
  PRIOR CONCURRENT THERAPY:
  -  No more than 1 prior chemotherapy regimen allowed
  -  At least 4 weeks since prior chemotherapy and recovered
  -  No prior radiotherapy
  -  Recovered from toxic effects of any prior therapy

Relevance to patient case: not relevant